Takuji Bando

This inventor holds 13 USPTO granted patents and 4 published patent applications, plus 6 CIPO patents and 5 EPO patents. Top assignees: Otsuka Pharmaceutical Company, Limited, Ostuka Pharmaceutical Co., Ltd.. Active years: 2011-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takuji Bando. Retrieved from https://idiyas.com/inventor/takuji-bando

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 4)

% Patents Active = 46.2

CIPO Patents = 6

EPO Patents = 5 (Patent Applications = 2)

Average Co-Inventor Count = 14.7

ph-index = 5

Forward Citations = 116(Granted Patents)

Location History:

Osaka, JP (2016)
Tokushima, JP (2011 - 2018)

Company Filing History:

12 out of 846

Otsuka Pharmaceutical Company, Limited

patents

1 out of 2

Ostuka Pharmaceutical Co., Ltd.

patents

Years Active: 2011-2018

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10150735 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2018-12-11),

2. 9359302 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2016-06-07),

3. 9278934 - Method for producing fine particles of aripiprazole anhydride crystals B (2016-03-08),

4. 8993761 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2015-03-31),

5. 8901303 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2014-12-02),

6. 8901130 - Low hygroscopic aripiprazole drug substance and processes for the preparation (2014-12-02),

7. 8703773 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2014-04-22),

8. 8703772 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2014-04-22),

9. 8642760 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2014-02-04),

10. 8580796 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2013-11-12),

11. 8399469 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2013-03-19),

12. 8017615 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2011-09-13),

13. 7910589 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof (2011-03-22),

Title: Takuji Bando - Innovator in Pharmaceutical Development

Introduction

Takuji Bando is a prominent inventor renowned for his contributions to the pharmaceutical industry, particularly in the formulation of aripiprazole. Based in Tokushima, Japan, he holds 13 patents that reflect his commitment to advancing medical science through innovative solutions.

Latest Patents

Among his recent achievements, Bando focuses on the development of low hygroscopic forms of aripiprazole. His patent outlines processes for preparing this drug substance, ensuring that it does not convert to a hydrate or lose its original solubility during prolonged storage. This innovation enhances the stability and effectiveness of medicinal preparations containing anhydrous aripiprazole crystals.

Career Highlights

Throughout his career, Takuji Bando has made significant strides while working with Otsuka Pharmaceutical Company, Limited and Otsuka Pharmaceutical Co. Ltd. His expertise and determination have been pivotal to the advancements in pharmaceutical formulations, reinforcing the importance of drug stability.

Collaborations

Bando has collaborated with notable coworkers such as Satoshi Aoki and Junichi Kawasaki, contributing to a dynamic environment that fosters creativity and innovation. Their teamwork has led to the successful development of cutting-edge solutions in the field of pharmaceuticals.

Conclusion

Takuji Bando exemplifies the spirit of innovation with his groundbreaking work in pharmaceutical development. His patents, particularly in the formulation of aripiprazole, demonstrate his dedication to improving drug stability and efficacy, which ultimately benefits patients around the world.

Profile summary based on public USPTO records.